Glepaglutide, a long-acting glucagon-like peptide-2 analog, alters postprandial intestinal hormone levels but not glucose homeostasis in patients with short bowel syndrome

Abstract

Rationale: Native glucagon-like peptide (GLP)-2 as well as GLP-2 analogs have been shown to improve intestinal function in patients with short bowel syndrome (SBS). Since the effects of GLP-2 on endogenous meal-stimulated intestinal hormone release and glucose homeostasis are largely unknown, we aimed to elucidate these relationships in patients with SBS treated with glepaglutide, a long-acting GLP-2 analog.